Pharmacometabolomics of response to sertraline and to placebo in major depressive disorder - possible role for methoxyindole pathway
about
Metabolomics: A Tool Ahead for Understanding Molecular Mechanisms of Drugs and DiseasesFrom Metabonomics to Pharmacometabonomics: The Role of Metabolic Profiling in Personalized MedicineModule-based association analysis for omics data with network structure.Metabolomics biomarkers to predict acamprosate treatment response in alcohol-dependent subjects.Altered KYN/TRP, Gln/Glu, and Met/methionine sulfoxide ratios in the blood plasma of medication-free patients with major depressive disorderAntidepressant treatment response is modulated by genetic and environmental factors and their interactions.Pharmacometabolomics: implications for clinical pharmacology and systems pharmacology.Elevated baseline serum glutamate as a pharmacometabolomic biomarker for acamprosate treatment outcome in alcohol-dependent subjects.Pharmacometabolomic Assessments of Atenolol and Hydrochlorothiazide Treatment Reveal Novel Drug Response PhenotypesPharmacometabolomic Assessment of Metformin in Non-diabetic, African Americans.Metabolomic Signatures for Drug Response Phenotypes: Pharmacometabolomics Enables Precision Medicine.Kynurenine pathway dysfunction in the pathophysiology and treatment of depression: Evidences from animal and human studiesTSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomicsMetabolomic signatures of drug response phenotypes for ketamine and esketamine in subjects with refractory major depressive disorder: new mechanistic insights for rapid acting antidepressantsPharmacometabolomics study identifies circulating spermidine and tryptophan as potential biomarkers associated with the complete pathological response to trastuzumab-paclitaxel neoadjuvant therapy in HER-2 positive breast cancer.Integration of pharmacometabolomics with pharmacokinetics and pharmacodynamics: towards personalized drug therapy.Pharmacometabolomics in Early-Phase Clinical Development.Pharmacometabonomics in humans: a new tool for personalized medicine.Peripheral biomarkers of major depression and antidepressant treatment response: Current knowledge and future outlooks.Emerging applications of metabolomics in drug discovery and precision medicine.Precision medicine for psychopharmacology: a general introduction.Drugs with antidepressant properties affect tryptophan metabolites differently in rodent models with depression-like behavior.Beta-defensin 1, aryl hydrocarbon receptor and plasma kynurenine in major depressive disorder: metabolomics-informed genomics.Evaluation of interleukin-6 and serotonin as biomarkers to predict response to fluoxetine.Insights into myalgic encephalomyelitis/chronic fatigue syndrome phenotypes through comprehensive metabolomics.Differentially expressed genes related to major depressive disorder and antidepressant response: genome-wide gene expression analysis
P2860
Q26827107-C11BE7B6-BB3B-4E6E-9E92-4F764061EAEFQ28067029-9DD944C6-8280-4AA9-8FC7-F45488053BD5Q30919427-F6226093-DB51-4D4B-AE1A-FAF776E68382Q33746846-36CF19BD-6561-4061-A102-B673FA7F69B3Q33884852-D5FB3CF4-6554-4C6F-A550-1A0D62413866Q33930731-F71FBBA1-4A65-43B5-AC35-CFBC0F2C1CB9Q35032056-7083F4B2-C8F9-440F-AF90-6222AFC52B77Q36043383-645B6D13-93F3-4E16-9F7D-61CA24B2787EQ36473120-4FCE5FC4-B622-414D-AF6D-F4FE3A04BCF0Q36999783-73486443-5716-44A8-8549-51724DD5C711Q37078812-A564DFB4-DD62-4ABA-AAF4-AF85FCC2C8F3Q37114639-412232D8-EF4D-43B5-AA9C-19F212F491E3Q37213132-DD480901-BED6-42FC-8C5E-C8F4DA2D9B28Q37307160-687DE5E8-1A7E-4CFF-91E5-64CDBC642A96Q37457684-B0304E43-22E6-4B8E-A23B-E4773E16B9AFQ37512208-70ED45B3-AC44-498D-9D42-8D7F46088468Q37701143-19B1A3F6-1EA2-4E8C-AC4B-44445A513465Q38452107-7CCB4DAA-BB5F-4879-9D16-164314293E03Q38657429-59998646-E2AF-4BB3-9588-646463902822Q38769103-DF483F46-DE3A-4319-A88A-6DD1CF877BB0Q38814860-8F72F3A5-C0FB-4ABB-8DCA-42A98D4A4EEAQ46383849-A8D3FE66-500A-43CC-AC72-706850F42B5DQ47659995-CE62C774-3DF3-45CB-944D-9E43C3EF49F1Q48059924-57B77E6A-632D-498E-8FFA-ED0C1959D237Q55646182-4AF96837-1AB7-4A49-BCE3-8A5FE8784FA3Q58802428-919FD682-5E0F-496A-9A3C-549D37151A09
P2860
Pharmacometabolomics of response to sertraline and to placebo in major depressive disorder - possible role for methoxyindole pathway
description
2013 nî lūn-bûn
@nan
2013 թուականին հրատարակուած գիտական յօդուած
@hyw
2013 թվականին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Pharmacometabolomics of respon ...... role for methoxyindole pathway
@ast
Pharmacometabolomics of respon ...... role for methoxyindole pathway
@en
Pharmacometabolomics of respon ...... role for methoxyindole pathway
@en-gb
Pharmacometabolomics of respon ...... role for methoxyindole pathway
@nl
type
label
Pharmacometabolomics of respon ...... role for methoxyindole pathway
@ast
Pharmacometabolomics of respon ...... role for methoxyindole pathway
@en
Pharmacometabolomics of respon ...... role for methoxyindole pathway
@en-gb
Pharmacometabolomics of respon ...... role for methoxyindole pathway
@nl
altLabel
Pharmacometabolomics of Respon ...... Role for Methoxyindole Pathway
@en
prefLabel
Pharmacometabolomics of respon ...... role for methoxyindole pathway
@ast
Pharmacometabolomics of respon ...... role for methoxyindole pathway
@en
Pharmacometabolomics of respon ...... role for methoxyindole pathway
@en-gb
Pharmacometabolomics of respon ...... role for methoxyindole pathway
@nl
P2093
P2860
P3181
P1433
P1476
Pharmacometabolomics of respon ...... role for methoxyindole pathway
@en
P2093
Erik Churchill
Eve Pickering
Hongjie Zhu
John A Rush
Marielle Delnomdedieu
Mikhail B Bogdanov
Ranga R Krishnan
Samantha Matson
Stephen H Boyle
Swati Sharma
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0068283
P407
P577
2013-01-01T00:00:00Z